Nature Communications (Sep 2019)
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
- Haoxin Li,
- Kevin Bullock,
- Carino Gurjao,
- David Braun,
- Sachet A. Shukla,
- Dominick Bossé,
- Aly-Khan A. Lalani,
- Shuba Gopal,
- Chelsea Jin,
- Christine Horak,
- Megan Wind-Rotolo,
- Sabina Signoretti,
- David F. McDermott,
- Gordon J. Freeman,
- Eliezer M. Van Allen,
- Stuart L. Schreiber,
- F. Stephen Hodi,
- William R. Sellers,
- Levi A. Garraway,
- Clary B. Clish,
- Toni K. Choueiri,
- Marios Giannakis
Affiliations
- Haoxin Li
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kevin Bullock
- Broad Institute of MIT and Harvard
- Carino Gurjao
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David Braun
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sachet A. Shukla
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Dominick Bossé
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Aly-Khan A. Lalani
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Shuba Gopal
- Broad Institute of MIT and Harvard
- Chelsea Jin
- Bristol-Myers Squibb
- Christine Horak
- Bristol-Myers Squibb
- Megan Wind-Rotolo
- Bristol-Myers Squibb
- Sabina Signoretti
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David F. McDermott
- Beth Israel Deaconess Medical Center
- Gordon J. Freeman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Stuart L. Schreiber
- Broad Institute of MIT and Harvard
- F. Stephen Hodi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- William R. Sellers
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Levi A. Garraway
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Clary B. Clish
- Broad Institute of MIT and Harvard
- Toni K. Choueiri
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Marios Giannakis
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-019-12361-9
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 6
Abstract
Immune-checkpoint inhibition therapy has achieved success in a subset of patients. Here the authors profiled about 200 relevant metabolites in patient serum samples from three independent immunotherapy trials and found the serum kynurenine/tryptophan ratio increases to be associated with worse overall survival.
